eISSN: 2299-0046
ISSN: 1642-395X
Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii
Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
3/2022
vol. 39
 
Share:
Share:
Original paper

An analysis of clinical effectiveness of electrochemotherapy in the treatment of advanced metastatic malignant melanoma performed in the eastern part of Central Europe: a single-centre experience

Marcin Ziętek
1, 2
,
Maciej Nowacki
1, 3
,
Jędrzej Wierzbicki
4
,
Adam Maciejczyk
2
,
Edyta Pawlak
5
,
Rafał Matkowski
2, 6

  1. Department of Oncology, Wroclaw Medical University, Wroclaw, Poland
  2. Second Department of Surgical Oncology,, Lower Silesian Oncology, Pulmonology and Hematology Center, Wroclaw, Poland
  3. Chair of Surgical Oncology, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Poland
  4. SSG Group, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Poland
  5. Breast Cancer Unit, Wroclaw Comprehensive Cancer Centre, Wroclaw, Poland
  6. Department of Experimental Therapy, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroclaw, Poland
Adv Dermatol Allergol 2022; XXXIX (3): 559-564
Online publish date: 2022/07/14
Article file
- An analysis.pdf  [0.18 MB]
Get citation
 
 

Introduction

Cutaneous malignant melanoma (MM) is still a challenging issue in the field of dermato-oncology alike surgical oncology and clinical oncology [1]. It is estimated that the incidence of this lethal skin cancer has rapidly increased in the last 5 decades. The middle European incidence ratio ranged from the number of 3 new diagnosed cases per 100,000 inhabitants in the early 1970’ to the ratio of 9 new diagnosed cases per 100,000 inhabitants in the beginning of the 21st century [2]. Cutaneous MM causes around 55,500 deaths per year worldwide and belongs to the highest mortality cancers, accounting for approximately 75% of deaths from all skin cancers [3]. An emerging issue among MM patients is late-stage diagnosis, as well as its biological predisposition to rapid growth and difficulties with obtaining control progression stage [4]. That is why in recent years, the treatment of MM in the advanced clinical stage has become a strategic and emerging issue. Currently, many interesting treatment options have been proposed for this specific group. The most currently evaluated clinical strategies include the development of immunotherapy, the use of targeted agents like BRAF and MEK inhibitors or novel products of oncolytic viral therapy [5, 6]. Moreover, among the significant group of patients, excluding those with distant metastases, surgery supported or replaced by radiotherapy, isolated perfusion hyperthermia and electrochemotherapy (ECT) are currently the first choice treatment. From the above-mentioned methods, the ECT has become an increasingly interesting direction in the development of local treatment of the advanced superficial tumours and/or their satellite and in-transit metastases [7, 8].

Aim

The aim of this study was to analyse the clinical effectiveness of the ECT in the treatment of advanced metastatic malignant melanoma in the group of patients hospitalized in the second Department of Surgical Oncology of the Wroclaw Comprehensive Cancer Centre, Poland.

Material and methods

Patients/Study group

There were 4 men and 1 woman (mean age: 70.2, range: 60–76) diagnosed with melanoma at varying grades of advancement of MM who have undergone the ECT (Table 1). Three patients had T2b primary tumour stage (dimension: 1.5–1.8 cm, with ulceration); one had T3 and one T4b (dimension: 10.5 cm). All patients before the ECT had primary tumours resected which were located in four out of five patients within the limbs and in one case within the trunk. Patient 3 presented a distant metastasis to the retroperitoneal space which was excised before the ECT and, as in patient 2, was diagnosed with BRAF positive melanoma. It is worth noting that patient 5 was successfully treated for sigmoid cancer (pT2N0M0) in 2015. Patient 1 was qualified to the ECT after almost 30 years from the diagnosis. In the rest of the patients the mean interval between diagnosis and the ECT cycle was 2 years and 3 months (6 months–4 years, 11 months).

Table 1

Patients’ characteristics

PatientSexAgeTNMPrimary tumour locationSite of metastasisBRAFDiagnosis
1F76T3N3M0Left thighLeft foot and legnegative1988
2M63T2bN3M0Pubic symphysisLeft groinpositiveDec 2016
3M76T4bN3M1aRight forearmRight forearmpositiveFeb 2018
4M76T2bN1cM0Right halluxRight foot and legnegativeJun 2017
5M60T2bN2bM0Right thighRight buttock and thighnegativeJul 2015

Patients were qualified for the ECT in different clinical situations, however, all of them already had a surgical intervention for the primary MM. In total, immunotherapy was administered in three patients, of whom two underwent radiotherapy (Table 2). All but one patient already had a lymphadenectomy which in patient 2 was performed for the second time. Moreover, patients 1 and 4 had multiple reoperations (9 and 7, respectively) of the in-transit metastases due to locoregionally relapsed disease and patient 5 underwent one such surgical procedure.

Table 2

Patients’ previous treatment

TreatmentPatient 1Patient 2Patient 3Patient 4Patient 5
RadiotherapyYesYes
ImmunotherapyT-VEC/PembrolizumabDabrafenib/TrametinibInterferon
Lymphadenectomy2111
Resection of the metastasis971

Procedure and clinical evaluation

The ECT was performed according to the European Standard Operating Procedures of Electrochemotherapy (ESOPE) [9]. Bleomycin was administered intravenously in patients under general endotracheal anaesthesia and in supine position before the procedure. The dosage was measured depending on the body surface. The electroporation procedure has started 8 min after intravenous injection of bleomycin. A square wave electroporator, Cliniporator model EPS02 (IGEA, Carpi, Italy), was used to deliver the electric pulses. Linear (N-20-4B) or hexagonal (N-20-HG and N-30-HG) electrodes measuring 20–30 mm in length, chosen by the clinician before the ECT, were used on all clinically evident in-transit metastases. Pulses, also chosen based on the clinician’s experience, were delivered in two ways: 1) sequences consisting of 4 high voltage pulses with 730 V amplitude and 100 µs duration; 2) sequences consisting of 8 high voltage pulses with 400 V amplitude and 100 µs duration. Detailed data about the whole procedures including time, duration of the pulses, measurement of the applied voltage and current were exported from the electroporator and then analysed.

The treatment response, evaluated 4 weeks after the procedure, was the mean of the response for each lesion based on Response Evaluation Criteria in Solid Tumours [10]. The site of the treatment was photographed on the day of the procedure, 1 month and 2 months later.

Results

Since the introduction of the ECT in the Wroclaw Comprehensive Cancer Centre, 6 procedures were performed in 5 patients. The dose of bleomycin varied from 26k to 30k UI (Table 3). In case of patient 4 during the first cycle of ECT the linear electrode was used. The rest of the patients were treated with hexagonal electrodes. In some patients, the accurate assessment of the number of lesions was impossible due to their fusion (Figure 1), therefore the description of the procedures included the number of electrode positions. In total, 377 (18–187) electrode placements have been performed to treat approximately 200 nodules. The length of the procedure, calculated from the beginning of the first to the end of the last electroporation, was closely related to the regional relapse of melanoma and lasted on average 10 min 41 s.

Table 3

ECT procedural details

PatientBleomycin dosageElectrodeNodules treatedElectrode placementsTime of the procedureOverall response
130k UIHexagonal12184 min 32 sPartial
230k UIHexagonal~30267 min 32 sPartial
326k UIHexagonal6214 min 50 sPartial
426k UILinear~256511 min 41 sProgressive disease
26k UIHexagonal~30608 min 5 sPartial
530k UIHexagonal~10018727 min 27sPartial
Figure 1

Comparison of treatment effects of well-separated and overlapping metastases in 2 patients. A – Patient 3 on the day of the procedure; B – patient 3 2 months after the procedure; C – patient 5 on the day of the procedure; D – patient 52 months after the procedure

/f/fulltexts/PDIA/47327/PDIA-39-47327-g001_min.jpg

After 5 out of 6 ECT procedures, partial treatment response has been achieved one month after the ECT. In patient 1, all of the lesions were reduced and 4 months after the procedure four of them were visible. Partial responses were also observed in patient 2, 3 and 5, however, in patient 3 three and in patient 5 one new, untreated lesion has appeared. In patient 4 after the first cycle of the ECT the treated nodules progressed. Moreover, one new lesion was found after the first ECT. In this case, first-line immunotherapy administered was ineffective and the second cycle of the ECT preceded by an amputation of the hallux was proposed. After the repeated cycle, partial response has been observed (Figure 2). In all but one patient, first or subsequent resections of the cutaneous metastasis were undertaken after the ECT. In total, reoperations were performed 5, 1, 1, 4 times in patients 1, 2, 3, and 4, respectively.

Figure 2

Patient with multiple in-transit metastases on the right foot and leg. A – On the day the second ECT was performed; B – 1 month follow-up; C – 2 months follow-up

/f/fulltexts/PDIA/47327/PDIA-39-47327-g002_min.jpg

Patients were followed until 30 November 2020. One patient died 1 year, 7 months and 3 days after the ECT despite the notable treatment response. The cause of death was a thromboembolic phenomenon correlated with aggravating clinical condition as a consequence of the course of MM. The mean time from the procedure to that date in the rest of the group was 1 year, 6 months and 6 days. In patients 2 and 4, long-term disease stabilization was achieved. Although the assessed response for the ECT was partial, the subsequent removal of the lesions in these patients did not allow for future recurrence. In long-term observation in patient 3 MM progressed and the multiple distant metastases (among others to the lymph nodes, kidneys and orbit) were diagnosed 4 months after the ECT. Patient 5 did not come for the last follow-up visit in November 2020 (5 months after the ECT) and a wider evaluation of his clinical condition was not possible.

Of note, an interesting correlation was observed during the study. Basal Cell Carcinoma was diagnosed and surgically excised in patients 1–3. Moreover, in patient 2 there was a relapse of BCC. In total, BCC was diagnosed twice before the melanoma and twice after. This observation is in agreement with the literature data about BCC as a risk factor for MM and an increased risk of subsequent skin cancer after the MM diagnosis [11, 12].

Discussion

Electrochemotherapy is a relatively novel and cost-efficient method of treatment of metastases in patients with advanced cutaneous melanoma [13, 14]. Since 2006, when the ESOPE established standardized details of the ECT procedure [10], the increasing popularity of the use of this method has been observed in cases of lack of response to treatment with other methods and in non-resectable lesions from MM [15]. Furthermore, high efficacy and excellent safety profile was proved for this method which resulted in the introduction of the ECT in several international guidelines [1618]. The authors are aware of a small study sample size, which is a relevant limitation of this article, especially in view of above-mentioned facts. However, despite the increasing role of ECT in the treatment of advanced MM, access to this method in Poland remains limited and it is available to patients only in a few specialized centres in the whole country.

Our paper presents the effects of treatment of patients with multiple lesions, involving whole limbs as well as individual lesions. In both situations it was possible to achieve the particular response with long-lasting stabilization of the disease, and even to prevent relapse during the course of the study. Moreover, as the treatment is well tolerated in case of progression it is possible to retreat the patient with another cycle [19].

Highly positive outcomes after the ECT cycle are consecutively repeated in recent studies. In a literature review published in 2018 and consisting of analysis of 11 articles from 2006–2017, the results of the ECT treatment of cutaneous MM from different centres were shown [20]. In total, the review gathered 502 patients with 2050 lesions and a mean overall response was 74% (complete response (CR) and partial response (PR) were 40% and 34%, respectively). In 2018, Al-Hadithy et al. reported the results of the prospective cohort study on superficial cancers of 48 patients, of whom 26 were diagnosed with melanoma [21]. In this group, in 24 cases good or partial response was achieved (92%). Very good clinical efficacy of the ECT was presented by the cancer centres collaborating within the International Network for Sharing Practices on Electrochemotherapy (INSPECT) [22]. Two hundred and eighty-three melanoma patients with 932 cutaneous lesions were included in the study. The OR and PR were 82% and 64%, respectively. Unfortunately, however, regardless of the encouraging clinical effectiveness of electroporation, some research groups reported lack of impact on overall survival [23, 24].

An important aspect for patients who suffer from advanced cutaneous melanoma is the impact of the skin-related symptoms on their quality of life [25]. Hence, in addition to the cosmetic effect, it is worth paying attention to the fear of recurrence and distress from the widespread of the nodules within the skin as well as ulceration and pain of the advanced cutaneous metastases [26]. Worth noting is that oncological treatment itself affects the patients’ life and may be refused due to possible complications. Multiple resections or limb amputations are especially harmful and negatively perceived by patients who suffer from MM [27]. Thus, less invasive therapeutic solutions may improve both the patient’s well-being and compliance.

Conclusions

In recent years the number of ECT procedures has been increasing systematically as well as the role in the treatment of cutaneous MM. An analysis presented in this paper confirmed that the ECT is an effective therapeutic approach in non-resectable and treatment-resistant in-transit metastases. Within the study period, except the positive response after the procedures, the stabilization and control over the relapse of MM was observed. Furthermore, what is especially important for the patients, visible reduction in the lesions and improvement of skin appearance positively influencing their quality of life was obtained. Although ECT is still under active investigation and further studies are necessary to consolidate the scientific evidence of utility of this form of treatment, it seems that properly selected groups of patients may get particular benefits even in the terminal stage of MM.

Acknowledgments

This research was financed through a subsidy by the Polish Ministry of Health, realized under the topic, according to the records in the Simple system with the number SUBZ.C280.22.001.

Conflict of interest

The authors declare no conflict of interest.

References

1 

Orzan OA, Șandru A, Jecan CR. Controversies in the diagnosis and treatment of early cutaneous melanoma. J Med Life 2015; 8: 132-41.

2 

Garbe C, Blum A. Epidemiology of cutaneous melanoma in Germany and worldwide. Skin Pharmacol Appl Skin Physiol 2001; 14: 280-90.

3 

Schadendorf D, van Akkooi ACJ, Berking C, et al. Melanoma. Lancet 2018; 392: 971-84.

4 

Tripp MK, Watson M, Balk SJ, et al. State of the science on prevention and screening to reduce melanoma incidence and mortality: the time is now. CA Cancer J Clin 2016; 66: 460-80.

5 

Lee CS, Thomas CM, Ng KE. An overview of the changing landscape of treatment for advanced melanoma. Pharmacotherapy 2017; 37: 319-33.

6 

Stadler S, Weina K, Gebhardt C, Utikal J. New therapeutic options for advanced non-resectable malignant melanoma. Adv Med Sci 2015; 60: 83-8.

7 

Colombo GL, Matteo SD, Mir LM. Cost-effectiveness analysis of electrochemotherapy with the Cliniporator vs other methods for the control and treatment of cutaneous and subcutaneous tumors. Ther Clin Risk Manag 2008; 4: 541-8.

8 

Bigi L, Galdo G, Cesinaro AM, et al. Electrochemotherapy induces apoptotic death in melanoma metastases: a histologic and immunohistochemical investigation. Clin Cosmet Investig Dermatol 2016; 9: 451-9.

9 

Mir LM, Gehl J, Sersa G, et al. Standard operating procedures of the electrochemotherapy: instructions for the use of bleomycin or cisplatin administered either systemically or locally and electric pulses by the Cliniporator™ by means of invasive or non-invasive electrodes. Eur J Cancer Suppl 2006; 4: 14-25.

10 

Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-47.

11 

Marghoob AA, Slade J, Salopek TG, et al. Basal cell and squamous cell carcinomas are important risk factors for cutaneous malignant melanoma. Screening implications. Cancer 1995; 75 (2 Suppl): 707-14.

12 

van der Leest RJ, Flohil SC, Arends LR, et al. Risk of subsequent cutaneous malignancy in patients with prior melanoma: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol 2015; 29: 1053-62.

13 

Kunte C, Letulé V, Gehl J, et al. Electrochemotherapy in the treatment of metastatic malignant melanoma: a prospective cohort study by InspECT. Br J Dermatol 2017; 176: 1475-85.

14 

Testori AAE, Blankenstein SA, van Akkooi ACJ. Surgery for metastatic melanoma: an evolving concept. Curr Oncol Rep 2019; 21: 98.

15 

Carrera C, Bennassar A, Ishioka P, et al. Desmoplastic melanoma on the nose: electrochemotherapy as an alternative treatment to local advanced disease. J Eur Acad Dermatol Venereol 2014; 28: 424-32.

16 

Aguado-Romeo MJ, Benot-López S, Romero-Tabares A. Electrochemotherapy for the treatment of unresectable locoregionally advanced cutaneous melanoma: a systematic review. Actas Dermosifiliogr 2017; 108: 91-7.

17 

Gehl J, Sersa G, Matthiessen LW, et al. Updated standard operating procedures for electrochemotherapy of cutaneous tumours and skin metastases. Acta Oncol 2018; 57: 874-82.

18 

Garbe C, Amaral T, Peris K, et al. European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment – Update 2019. Eur J Cancer 2020; 126: 159-77.

19 

Quaglino P, Mortera C, Osella-Abate S, et al. Electrochemotherapy with intravenous bleomycin in the local treatment of skin melanoma metastases. Ann Surg Oncol 2008; 15: 2215-22.

20 

Wichtowski M, Murawa D. Electrochemotherapy in the treatment of melanoma. Contemp Oncol 2018; 22: 8-13.

21 

Al-Hadithy N, Dehnel A, George A, et al. Patient reported outcomes in prospective cohort study of electrochemotherapy. Int J Surg 2018; 52: 110-9.

22 

Clover AJP, de Terlizzi F, Bertino G, et al. Electrochemotherapy in the treatment of cutaneous malignancy: outcomes and subgroup analysis from the cumulative results from the pan-European International Network for Sharing Practice in Electrochemotherapy database for 2482 lesions in 987 patients (2008-2019). Eur J Cancer 2020; 138: 30-40.

23 

Gaudy C, Richard MA, Folchetti G, et al. Randomized controlled study of electrochemotherapy in the local treatment of skin metastases of melanoma. J Cutan Med Surg 2006; 10: 115-21.

24 

Ricotti F, Giuliodori K, Cataldi I, et al. Electrochemotherapy: an effective local treatment of cutaneous and subcutaneous melanoma metastases. Dermatol Ther 2014; 27: 148-52.

25 

Bonnaud-Antignac A, Bourdon M, Dréno B, et al. Coping strategies at the time of diagnosis and quality of life 2 years later: a study in primary cutaneous melanoma patients. Cancer Nurs 2017; 40: E45-53.

26 

Mir-Bonafe JM, Vilalta A, Alarcon I, et al. Electrochemotherapy in the treatment of melanoma skin metastases: a report on 31 cases. Actas Dermosifiliogr 2015; 106: 285-91.

27 

Kasparian NA, McLoone JK, Butow PN. Psychological responses and coping strategies among patients with malignant melanoma: a systematic review of the literature. Arch Dermatol 2009; 145: 1415-27.

Copyright: © 2022 Termedia Sp. z o. o. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
 
Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.